Oncodesign Precision Medicine (OPM) has received €5.6 million in funding for the DEMOCRITE project, aimed at demonstrating the efficacy of OPM-101 in treating Inflammatory Bowel Disease (IBD).
OPM-101, derived from OPM’s Nanocyclix® platform, inhibits RIPK2, a key regulator of cell death and inflammation. The project focuses on Immune-Induced Ulcerative Colitis (IIUC), a severe form of IBD.
The funding will support completing Phase 1 and Phase 2a clinical trials to establish proof of concept for OPM-101’s effectiveness in IIUC patients. The project also aims to secure a commercial partnership for the continued development of OPM-101 in IBD treatment.
OPM-101 is one of several kinase inhibitor molecules derived from the Nanocyclix® platform. Kinases are enzymes that regulate essential cellular functions, making them promising targets for precision medicine.
The success of the DEMOCRITE project will advance OPM’s mission to establish a precision medicine sector in France and solidify its position as a leader in kinase inhibitor development. By targeting RIPK2, OPM-101 has the potential to provide a novel and effective treatment option for patients with IBD.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
